BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32682383)

  • 1. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells.
    Tang X; Zheng Y; Jiao D; Chen J; Liu X; Xiong S; Chen Q
    Anticancer Agents Med Chem; 2021; 21(6):747-755. PubMed ID: 32682383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer.
    Xia X; Pi W; Lan Y; Wu X; Lv D; Meng Y; Yang H; Wang W
    Anal Cell Pathol (Amst); 2022; 2022():4484211. PubMed ID: 35757014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer.
    Li H; Liu Y; Liu X; Zhao D; Liu J; Cheng Y
    Anticancer Drugs; 2020 Nov; 31(10):1057-1064. PubMed ID: 32694423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
    Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
    Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genistein exhibits anti-cancer effects via down-regulating FoxM1 in H446 small-cell lung cancer cells.
    Tian T; Li J; Li B; Wang Y; Li M; Ma D; Wang X
    Tumour Biol; 2014 May; 35(5):4137-45. PubMed ID: 24379139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
    Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
    Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
    Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evodiamine induces G2/M arrest and apoptosis via mitochondrial and endoplasmic reticulum pathways in H446 and H1688 human small-cell lung cancer cells.
    Fang C; Zhang J; Qi D; Fan X; Luo J; Liu L; Tan Q
    PLoS One; 2014; 9(12):e115204. PubMed ID: 25506932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and invasion of small-cell lung cancer (SCLC) cells.
    Wang ZX; Lu BB; Yang JS; Wang KM; De W
    J Surg Res; 2011 Nov; 171(1):127-35. PubMed ID: 20338593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NEAT 1 knockdown enhances the sensitivity of human non-small-cell lung cancer cells to anlotinib.
    Gu G; Hu C; Hui K; Chen T; Zhang H; Jiang X
    Aging (Albany NY); 2021 May; 13(10):13941-13953. PubMed ID: 33982669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Apatinib Combined with CCI-779 Inhibits the Proliferation and Migration of Small Cell Lung Cancer NCI-H446 Cells In Vitro].
    Liu C; Zhang H; Li Y; Zhang Z; Shi R; Xu S; Zhu G; Wang P; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2020 Apr; 23(4):216-222. PubMed ID: 32209188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway.
    He C; Wu T; Hao Y
    Biochem Biophys Res Commun; 2018 Sep; 503(4):3093-3099. PubMed ID: 30146257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resveratrol inhibits viability and induces apoptosis in the small‑cell lung cancer H446 cell line via the PI3K/Akt/c‑Myc pathway.
    Li W; Li C; Ma L; Jin F
    Oncol Rep; 2020 Nov; 44(5):1821-1830. PubMed ID: 32901891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
    Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.
    Xu P; Wang H; Pan H; Chen J; Deng C
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):183-196. PubMed ID: 34997858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anlotinib inhibits the progress of colorectal cancer cells by antagonizing VEGFR/JAK2/STAT3 axis.
    Jia ZX; Zhang Z; Li Z; Li A; Xie YN; Wu HJ; Yang ZB; Zhang HM; Zhang XM
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2331-2343. PubMed ID: 33755971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anlotinib suppressed tumor cell proliferation and migration in hypopharyngeal carcinoma.
    Song H; Song Q; Zhao X; Yang Y; Mou Y; Li Y; Song X
    Braz J Otorhinolaryngol; 2024; 90(2):101397. PubMed ID: 38330738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway.
    Wang L; Xu L; Han S; Zhu X
    Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer.
    Yang X; Di J; Zhang Y; Zhang S; Lu J; Liu J; Shi W
    Biomed Pharmacother; 2012 Apr; 66(3):221-7. PubMed ID: 22425182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance of human small cell lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Yu XS; Du J; Fan YJ; Liu FJ; Cao LL; Liang N; Xu DG; Zhang JD
    Oncotarget; 2016 Nov; 7(47):76827-76839. PubMed ID: 27765907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.